OMRIX BIOPHARMACEUTICALS: what changed
What changed
OMRIX BIOPHARMACEUTICALS
NACE 46.460, Wholesale of pharmaceutical and medical goods
filed annual accounts (NBB)
Net result for the year
€31,966
2024 · €12,947+€19,018
Equity
€18.5m
2024 · €18.4m+€31,966
Cash
€106,978
2024 · €113,080-€6,102
Balance sheet total
€66.5m
2024 · €48.2m+€18.3m
Largest movements
Assets
- Stocks and contracts +€24.7m
up €24.7m (+87.1%), from €28.4m to €53.1m
- Receivables within one year -€6.4m
down €6.4m (-32.4%), from €19.7m to €13.3m
of which Trade receivables: -€6.3m
Equity and liabilities
- Other debts +€11.3m
up €11.3m (+83.0%), from €13.6m to €24.9m
- Trade debts +€6.7m
up €6.7m (+43.9%), from €15.3m to €22.0m
- Accrued charges and deferred income +€882,594
new in 2025: €882,594
Income statement
- Goods and materials +€8.6m
up €8.6m (+8.6%), from €99.1m to €107.7m
of which Purchases: +€46.7m
- Turnover +€6.5m
up €6.5m (+6.5%), from €100.4m to €107.0m
- Financial income +€2.1m
up €2.1m (+15,693%), from €13,640 to €2.2m
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Result 2024
€12,947
Turnover
+€6.5m
Goods and materials
-€8.6m
Services and other goods
+€12,234
Staff costs
-€3,621
Write-downs
-€422,681
Other operating items
+€1
Financial income
+€2.1m
Financial charges
+€329,391
Taxes
-€5,947
Result 2025
€31,966
raises the resultlowers the resultnot broken down further in the accounts
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
From operations
-€6,102
Investment
€0
Financing
€0
Cash 2024
€113,080
From operations (derived)
-€6,102
Net result for the year
+€31,966
Stocks and contracts
-€24.7m
Receivables within one year
+€6.4m
Trade debts
+€6.7m
Tax, wage and social debts
-€590,476
Other debts
+€11.3m
Accrued charges and deferred income
+€882,594
Cash 2025
€106,978
brings cash intakes cash out
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €48,201,361 | €66,521,607 | +€18.3m | +38.0% |
| Current assets | 29/58 | €48,201,361 | €66,521,607 | +€18.3m | +38.0% |
| Stocks and contracts in progress | 3 | €28,355,773 | €53,066,009 | +€24.7m | +87.1% |
| Stocks | 30/36 | €28,355,773 | €53,066,009 | +€24.7m | +87.1% |
| Goods purchased for resale | 34 | €28,355,773 | €53,066,009 | +€24.7m | +87.1% |
| Amounts receivable within one year | 40/41 | €19,732,508 | €13,348,620 | -€6.4m | -32.4% |
| Trade receivables | 40 | €18,189,127 | €11,891,168 | -€6.3m | -34.6% |
| Other amounts receivable | 41 | €1,543,381 | €1,457,452 | -€85,929 | -5.6% |
| Cash at bank and in hand | 54/58 | €113,080 | €106,978 | -€6,102 | -5.4% |
| Total equity and liabilities | 10/49 | €48,201,361 | €66,521,607 | +€18.3m | +38.0% |
| Equity | 10/15 | €18,418,446 | €18,450,412 | +€31,966 | +0.2% |
| Contributions | 10/11 | €443,256 | €443,256 | = | 0.0% |
| Capital | 10 | €61,500 | €61,500 | = | 0.0% |
| Issued capital | 100 | €61,500 | €61,500 | = | 0.0% |
| Contributions outside capital | 11 | €381,756 | €381,756 | = | 0.0% |
| Share premium | 1100/10 | €381,756 | €381,756 | = | 0.0% |
| Reserves | 13 | €1,347,579 | €1,347,579 | = | 0.0% |
| Non-distributable reserves | 130/1 | €1,347,579 | €1,347,579 | = | 0.0% |
| Legal reserve | 130 | €1,347,579 | €1,347,579 | = | 0.0% |
| Profit (loss) carried forward | 14 | €16,627,611 | €16,659,577 | +€31,966 | +0.2% |
| Amounts payable | 17/49 | €29,782,914 | €48,071,195 | +€18.3m | +61.4% |
| Amounts payable within one year | 42/48 | €29,782,914 | €47,188,601 | +€17.4m | +58.4% |
| Trade debts | 44 | €15,275,478 | €21,985,779 | +€6.7m | +43.9% |
| Suppliers | 440/4 | €15,275,478 | €21,985,779 | +€6.7m | +43.9% |
| Taxes, remuneration and social security | 45 | €917,454 | €326,978 | -€590,476 | -64.4% |
| Taxes | 450/3 | €889,461 | €299,413 | -€590,048 | -66.3% |
| Remuneration and social security | 454/9 | €27,993 | €27,565 | -€428 | -1.5% |
| Other amounts payable | 47/48 | €13,589,983 | €24,875,844 | +€11.3m | +83.0% |
| Accrued charges and deferred income | 492/3 | - | €882,594 | +€882,594 | |
| Operating income | 70/76A | €100,412,672 | €106,951,096 | +€6.5m | +6.5% |
| Turnover | 70 | €100,412,672 | €106,951,096 | +€6.5m | +6.5% |
| Operating charges | 60/66A | €99,502,708 | €108,486,176 | +€9.0m | +9.0% |
| Goods for resale, raw materials and consumables | 60 | €99,091,346 | €107,660,747 | +€8.6m | +8.6% |
| Purchases | 600/8 | €86,104,613 | €132,793,664 | +€46.7m | +54.2% |
| Change in stocks: decrease (increase) | 609 | €12,986,734 | -€25,132,917 | -€38.1m | |
| Services and other goods | 61 | €249,965 | €237,731 | -€12,234 | -4.9% |
| Remuneration, social security and pensions | 62 | €161,396 | €165,017 | +€3,621 | +2.2% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) | 631/4 | - | €422,681 | +€422,681 | |
| Non-recurring operating charges | 66A | €1 | €0 | -€1 | -100% |
| Operating profit (loss) | 9901 | €909,964 | -€1,535,080 | -€2.4m | |
| Financial income | 75/76B | €13,640 | €2,154,259 | +€2.1m | +15,693% |
| Recurring financial income | 75 | €13,640 | €2,154,259 | +€2.1m | +15,693% |
| Income from financial fixed assets | 750 | €13,640 | €0 | -€13,640 | -100% |
| Other financial income | 752/9 | - | €2,154,259 | +€2.2m | |
| Financial charges | 65/66B | €904,385 | €574,994 | -€329,391 | -36.4% |
| Recurring financial charges | 65 | €904,385 | €574,994 | -€329,391 | -36.4% |
| Other financial charges | 652/9 | €904,385 | €574,994 | -€329,391 | -36.4% |
| Profit (loss) for the period before taxes | 9903 | €19,220 | €44,185 | +€24,965 | +130% |
| Income taxes | 67/77 | €6,272 | €12,219 | +€5,947 | +94.8% |
| Taxes | 670/3 | €6,272 | €12,219 | +€5,947 | +94.8% |
| Profit (loss) for the period | 9904 | €12,947 | €31,966 | +€19,018 | +147% |
| Profit (loss) for the period to be appropriated | 9905 | €12,947 | €31,966 | +€19,018 | +147% |
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Compare this company with its sector.Sector benchmark
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 2 November 2026 via checked.be.